Call us: 1.405.235.2305
info@i2E.org
  • Events
  • News
  • Resources
  • Library
  • Love’s Cup
i2Ei2Ei2Ei2E
  • About
  • Entrepreneurship
    • Venture Advisory Services
    • Love’s Entrepreneur’s Cup
  • e3
  • Concept Fund
  • iMCI
  • Portfolio
  • Contact

Selexys is a pharmaceutical company that developed a platform of Selectin Inhibition Technology consisting of therapies that target P-selectin glycoprotein ligand-1 (PSGL-1) and P-selectin to treat pain among those with sickle cell disease.

Year Founded: 2005

Year Partnered: 2009

Category: Biotech/Pharma

Fund: Accelerate, Oklahoma Seed Capital Fund  

Acquired in 2017 by Novartis

i2E-300dpi-Trans-Light
  • Events
  • News
  • Resources
  • Library
  • Love’s Cup

Oklahoma City Office

840 Research Parkway, Suite 250
OKC, OK 73104
PHONE 405/235-2305
Click HERE for printable map with directions.

Tulsa Office

618 E. Third Street, Suite 1
Tulsa, OK 74120
PHONE 918/582-5592
Click HERE for printable map with directions.
Copyright 2020 i2E, Inc. | All Rights Reserved
  • About
  • Entrepreneurship
    • Venture Advisory Services
    • Love’s Entrepreneur’s Cup
  • e3
  • Concept Fund
  • iMCI
  • Portfolio
  • Contact
i2E